ProQR Announces R&D Day in New York on June 15
May 09 2017 - 7:00AM
Key updates:
ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced a Research
& Development Day for investors hosted by the Company’s
management team and several key opinion leaders. The event will
also be webcast.
The R&D Day will feature presentations by ProQR management
on the progress on its pipeline, including a review and
introduction of several near- and medium term value drivers. In
addition, several leading opinion leaders will discuss the state of
the art in research and development on critical areas of the
company’s pipeline including CF, inherited blindness, debilitating
skin diseases and RNA technologies.
“Following a significant effort to build a diversified product
portfolio over the last 5 years, we now have a pipeline that
includes two clinical programs, one pre-clinical program and two
programs ready to enter development,” said Daniel de Boer, CEO of
ProQR. “We’re looking forward to provide an update on the
development programs and shine some light on the promising pipeline
of discovery programs and a novel RNA editing technology.”
“Over the last several decades the RNA space has matured
significantly. With our management and scientific resources we
believe we are well positioned to unlock the field’s substantial
potential,” said Gerard Platenburg, Chief Innovation Officer at
ProQR. “We apply the use of RNA based therapeutics with the goal to
make an impact for patients with several severe genetic diseases.
Our scientific efforts have also led to a novel proprietary RNA
editing platform, called Axiomer, which in our view is the next
step in RNA therapeutics, on which we will elaborate at the R&D
day.”
R&D Day Event details
On Thursday, June 15, 2017 ProQR will host an R&D day in New
York, NY from 8:00am to 1:00pm ET. Please email Ronen Abergel
rabergel@troutgroup.com to receive more information and to reserve
a seat.
Webcast
The live and archived webcast of the presentation will be
accessible from the ‘Investor Relations’ section of ProQR’s website
(www.proqr.com) under ‘Events and Presentations’. The archived
webcast will be available for 90 days following the presentation
date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through
the creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as cystic fibrosis, Leber’s
congenital amaurosis Type 10 and dystrophic epidermolysis
bullosa. Based on our unique proprietary RNA repair platform
technologies we are growing our pipeline with patients and loved
ones in mind. *Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements are based on management’s beliefs and
assumptions and on information available to management only as of
the date of this press release. These forward-looking statements
include, but are not limited to, statements regarding the
therapeutic potential of our RNA technology, our innovation
programs and pipeline, our discovery efforts and capabilities and
our R&D day. Our actual results could differ materially from
those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with our
clinical development activities, manufacturing processes and
facilities, regulatory oversight, product commercialization,
intellectual property claims, and the risks, uncertainties and
other factors in our filings made with the Securities and Exchange
Commission, including certain sections of our annual report filed
on Form 20-F. Given these risks, uncertainties and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Contact:Smital ShahChief Financial OfficerT: +1
415 231 6431ir@proqr.com
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Apr 2023 to Apr 2024